0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-7 R alpha

IL-7 R alpha

Brief Information

Name:Interleukin-7 receptor subunit alpha
Target Synonym:Interleukin-7 receptor subunit alpha,CDw127,IL-7RA,IL-7 receptor subunit alpha,IL7R,Interleukin 7 Receptor,CD127 Antigen,IL-7R-Alpha,Interleukin 7 Receptor Isoform H5-6,Interleukin 7 Receptor Alpha Chain,CD127,IL7RA,ILRA,Interleukin-7 Receptor alpha Subun
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

IL7-H5258-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Human IL-7 R alpha, Mouse IgG2a Fc Tag (Cat. No. IL7-H5258) on CM5 chip via anti-mouse antibodies surface can bind ActiveMax® Human IL-7, Tag Free (Cat. No. IL7-H4219) with an affinity constant of 13.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

IL7-H82F8-ELISA
Biotinylated Human IL-7 R alpha, Fc,AvitagBiotinylated Human IL-7 R alpha, Fc,Avitag (Cat. No. IL7-H82F8) ELISA bioactivity

Immobilized ActiveMax® Human IL-7, Tag Free (Cat. No. IL7-H4219) at 10 μg/mL (100 μL/well) can bind Biotinylated Human IL-7 R alpha, Fc,Avitag (Cat. No. IL7-H82F8) with a linear range of 139 ng/mL (QC tested).

Synonym Name

IL7Ra,CD127

Background

Interleukin-7 receptor subunit alpha (IL7Ra) is also known as CD antigen CD127, which belongs to the type I cytokine receptor family and type 4 subfamily. IL7Ra /CD127 contains 1 fibronectin type-III domain. IL7Ra /CD127 is expressed on various cell types, including naive and memory T cells and many others. IL7Ra /CD127 is receptor for interleukin-7 and also acts as a receptor for thymic stromal lymphopoietin (TSLP). The IL7 receptor is a heterodimer of IL7R and IL2RG. The TSLP receptor is a heterodimer of CRLF2 and IL7R.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GSK-2618960 GSK-2618960 Phase 2 Clinical Glaxosmithkline Plc Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Sjogren's Syndrome Details
BNT-152 BNT-152 Phase 1 Clinical Biontech Se Solid tumours Details
OSE-127 OSE-127; S-95011 Phase 2 Clinical Effimune Sjogren's Syndrome; Colitis, Ulcerative; Inflammation Details
Interleukin-7 (Revimmune SAS) rhIL-7; CYT-107; CYT-99-007 Phase 2 Clinical Cytheris Mycobacterium Infections, Nontuberculous; Melanoma; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Hepatitis C; Lymphopenia; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; HIV Infections; Myeloproliferative Disorders; Coronavirus Disease 2019 (COVID-19); Sepsis; Hepatitis B, Chronic; Shock, Septic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Kidney Neoplasms Details
Efineptakin alfa (Genexine/NeoImmuneTech) GX-I7; TJ-107; NT-I7 Phase 2 Clinical Genexine Inc Solid tumours; Carcinoma, Merkel Cell; Glioblastoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Coronavirus Disease 2019 (COVID-19); Papillomavirus Infections; Brain Neoplasms; Colorectal Neoplasms; Cervical Intraepithelial Neoplasia; Carcinoma, Squamous Cell; Glioma; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

totop